Immunovant (IMVT) Other Non-Current Assets (2018 - 2026)

Immunovant (IMVT) has 3 years of Other Non-Current Assets data on file, last reported at $7.7 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 0.81% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 0.81% YoY) and the FY2026 annual result came in at $7.7 million, up 0.81% from the prior year.
• Other Non-Current Assets retreated to $7.7 million in Q1 2026, from $8.9 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $8.9 million in Q2 2025 to a low of $7.6 million in Q4 2024.
• A 3-year average of $8.2 million and a median of $7.7 million in 2026 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2025 — Other Non-Current Assets climbed 17.13% — and 2026, when it rose 0.81%.
• Tracing IMVT's Other Non-Current Assets over 3 years: stood at $7.6 million in 2024, then increased by 17.13% to $8.9 million in 2025, then dropped by 13.92% to $7.7 million in 2026.
• The last three Other Non-Current Assets figures came in at $7.7 million (Q1 2026), $8.9 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.